Monopar Therapeutics (NASDAQ:MNPR) Earns Buy Rating from Analysts at Rodman & Renshaw

Rodman & Renshaw initiated coverage on shares of Monopar Therapeutics (NASDAQ:MNPR) in a report published on Friday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $50.00 target price on the stock.

Separately, HC Wainwright raised their price target on Monopar Therapeutics from $2.00 to $6.00 and gave the company a buy rating in a report on Wednesday, August 14th.

Monopar Therapeutics Price Performance

Monopar Therapeutics stock opened at $5.50 on Friday. Monopar Therapeutics has a fifty-two week low of $1.37 and a fifty-two week high of $8.65. The firm has a market capitalization of $96.16 million, a PE ratio of -10.58 and a beta of 1.26. The company’s 50-day moving average is $3.51 and its 200-day moving average is $3.51.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings results on Friday, August 9th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). As a group, analysts expect that Monopar Therapeutics will post -1.93 EPS for the current year.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.